In a new study, patients taking statins reported experiencing symptoms that were identical to those experienced while taking placebo pills. Researchers suggest that the nocebo effect may be the cause of these side effects, rather than an actual pharmacological effect of the drug.
A new model predicts the risk of severe side effects in cancer patients during chemotherapy by analyzing genetic signatures. The study identified a network of genes linked to bone marrow toxicity and developed a classification system to predict patient risk.
New analysis shows HPV vaccines are safe for males, with similar side effects to females. The study evaluated reports of adverse events from the U.S. Vaccine Adverse Event Reporting System between 2006 and 2018.
A survey of nearly 400 cancer survivors found that 87% experienced sexual side effects, but most were not formally asked by their oncologist. Female patients were particularly unlikely to be discussed with. Researchers recommend using a standard questionnaire to initiate conversations and improve patient experience.
Researchers at UCI and CHUV/UNIL have developed a new cancer treatment that uses ultra-high dose rate radiation therapy to eliminate brain tumors without causing significant side effects. This breakthrough technique, known as FLASH-RT, has shown promising results in mice and has the potential to be used for a range of cancer types.
A study published in Communications Biology found that inflammation from high IL-6 levels leads to psoriasis-like dermatitis. Researchers propose targeting IL-6 as a potential approach to preventing the condition.
A new drug, vamorolone, has shown promise in reducing side effects associated with current steroid treatments for Duchenne muscular dystrophy. Interim results from a 24-month clinical trial suggest that vamorolone may retain or improve the therapeutic benefits of steroids while minimizing risks.
Researchers at Lund University have discovered biomarkers to predict how type 2 diabetes patients will respond to metformin treatment. The study, conducted on 363 participants, shows promise for personalized therapy and reducing side effects.
Researchers at TUM have found that DNA binding is essential for the anti-inflammatory effect of steroids like cortisone. This discovery refutes the common theory that steroids' effects are based on protein-to-protein interaction, and opens up new avenues for developing cortisone alternatives with fewer side effects.
Researchers developed a machine learning predictive model to predict nephrotoxicity risk in testicular cancer patients using Danish patient data. The model correctly predicted 67% of high-risk patients and 92% of low-risk patients who did not develop nephrotoxicity.
A study in the New England Journal of Medicine has found that dose escalation of hydroxyurea treatment is more effective and has similar side effects than a lower fixed dose for children with sickle cell anemia in Uganda. The results have global implications and can potentially improve treatment outcomes worldwide.
A study published in the New England Journal of Medicine has found that dose escalation of hydroxyurea treatment is more effective and has similar side effects than a lower fixed dose for children with sickle cell anemia in Uganda. The findings have global implications and could impact use of hydroxyurea worldwide.
A new drug lead has been developed to treat type 2 diabetes, improving blood sugar levels without nausea and weight loss. The research combines two molecules using a novel technique called 'corrination', reducing vomiting compared to existing GLP-1R agonists.
A $26.9-million project aims to create rapidly acting, effective, and safe psychiatric medications by targeting G protein-coupled receptors. The research seeks to overcome the limitations of existing drugs with severe side effects.
A novel treatment for advanced mesothelioma has been shown to be safe and effective, with a 70.3% disease control rate and median overall survival rate of 8.5 months. The transarterial chemoperfusion treatment may improve the quality of life for patients who have few treatment options.
The ADVOCATE study demonstrates avacopan's effectiveness in reducing corticoid use and achieving sustained remission in patients with AAV, particularly those with renal involvement. The treatment also showed improved outcomes with lower infection rates compared to standard immunosuppressive therapy.
Researchers have developed biodegradable polymer fibres infused with nimodipine to prevent nerve cell death after brain surgery. The treatment reduces side effects and minimizes blood pressure risks, offering a promising alternative to intravenous administration.
Researchers found that combining rosiglitazone, a popular but abandoned diabetes treatment, with another drug called Compound A can enhance its effectiveness while reducing side effects such as weight gain and fluid retention. The study suggests that using lower doses of rosiglitazone may be sufficient to achieve similar results.
Scientists from HKBU developed a novel approach to manipulating molecular chirality using helical metal nanostructures. This method eliminates potential side effects associated with drugs containing molecules in incorrect chiral arrangements, enabling the mass production of purer and cheaper drugs.
Researchers created a brain-sparing amphetamine, PEGyAMPH, that avoids cardiovascular side effects and addictive properties. It stimulates lipolysis and thermogenesis to promote fat breakdown and weight loss.
A University of Colorado Cancer Center study reveals significant variation in how drug side effects are reported, potentially leading to misinformation about a drug's safety. The study suggests standardizing reporting methods could improve the accuracy of risk assessments and drug licensing.
A case series of lung cancer patients taking osimertinib (Tagrisso) revealed a rare twist in the right side of their colon, cecal volvulus. Doctors using this drug with EGFR+ non-small cell lung cancer patients should watch for these cases alongside more expected side effects.
The NETTER-2 study is a Phase III clinical trial evaluating Lutathera's efficacy and safety in treating Grade 2 and 3 advanced GEP-NETs. The primary objective is to prolong Progression Free Survival in patients with high proliferation rate tumors.
Researchers have identified the mechanism behind the large drop in blood pressure caused by intravenous paracetamol, which affects critically ill patients. By understanding this process, they believe a new co-therapy design is possible to prevent the side effect.
A study found that NLX-112 reduced dyskinesia and improved movement symptoms in marmosets with Parkinson's-like symptoms. The results suggest that the drug has potential as a future treatment for people with Parkinson's, offering hope for those affected by debilitating movement problems.
A new study has found that the guideline-recommended diuretic chlorthalidone causes more serious side effects, including hypokalemia and kidney problems, compared to hydrochlorothiazide. The study analyzed data from over 730,000 individuals treated for hypertension.
Researchers at the University of Sydney have successfully developed pain-killing neurons using human stem cells, providing lasting relief in mice without side effects. The next step is to conduct safety tests in rodents and pigs before moving to human trials within five years.
A new oral pill, elagolix, has been shown to effectively reduce heavy menstrual bleeding in women with uterine fibroids. The study found that 80.4% of women treated with elagolix alone experienced a 50% reduction in bleeding, compared to 9.6% in the placebo group.
Researchers at the University of Freiburg have developed a light therapy approach that successfully treats severe autoimmune reactions in cancer patients. The extracorporeal photopheresis (ECP) treatment activates immune cells to stop inflammation, offering a promising alternative to cortisone therapy.
Researchers have developed a new approach to improving spinal fusion procedures and repairing broken bones. By delivering a potent bone-forming protein called BMP using a heparin mixture, they significantly reduced undesired bone growth outside of targeted repair areas in rat femurs.
A study published in JAMA Oncology found that proton therapy is just as effective as X-ray radiation therapy in treating cancer, but causes fewer side effects and lower hospitalization rates. This could lead to improved quality of life for patients and reduced healthcare costs.
Researchers found proton therapy significantly lowers the risk of severe side effects such as hospitalization, while maintaining similar cure rates and effectiveness compared to traditional photon radiation. The study suggests proton therapy offers a way to reduce serious side effects without sacrificing treatment efficacy.
Researchers developed a mathematical model to predict cancer drug side effects by analyzing genetic mutations in the UGT1A1 enzyme. The model was able to accurately predict the ability of UGT1A1 mutants to metabolize anti-cancer agents, offering potential for personalized treatment and reducing severe side effects.
A phase two trial found that belantamab mafodotin, a BCMA-targeting antibody-drug conjugate, achieved durable responses in nearly a third of patients with relapsed or refractory multiple myeloma. The therapy demonstrated significant tumor reduction and improved survival rates compared to standard treatments.
Engineers at Duke University create a bandage that traps and holds the pro-healing molecule adenosine, accelerating callus formation and vascularization to improve bone repair. The results show better bone formation, higher bone volume, and better vascularization in mice treated with adenosine-laced bandages.
A study by University of Cincinnati researchers found that certain antidepressant medications cause more side effects in children and adolescents with OCD and anxiety disorders. SSRIs were associated with increased rates of agitation, while SNRIs showed no significant link to suicidality.
Researchers found that over half of patients with reported penicillin allergies could take antibiotics from the same drug class, reducing hospital costs by nearly $21,500. The study's results suggest a multi-disciplinary approach to optimizing therapy in patients with penicillin allergies.
Researchers discovered that an orally administered liquid salt called Choline and Geranate (CAGE) can physically reduce fat absorption and slow down weight gain in rats. CAGE prevents fats from being absorbed into the bloodstream, leading to a significant reduction in body weight.
Researchers at Martin-Luther-Universität Halle-Wittenberg have developed biodegradable rods containing an antibiotic to treat periodontal disease, reducing side effects and inflammation. The innovative treatment uses a combination of minocycline and magnesium stearate, releasing the antibiotic slowly and locally in the mouth.
A new study published in PNAS found that suvorexant, a recently approved insomnia treatment, has fewer physical side effects compared to commonly prescribed hypnotics. The treatment specifically targets brain receptors involved in wakefulness, reducing impairments in body balance upon awakening.
A nationwide survey of over 400 US adults with cancer found that nearly all patients felt confident in their treatment decisions but had gaps in knowledge about potential side effects. The study highlights the need for more informed patient counseling and coordination between oncology disciplines to manage treatment-related side effects.
A single dose of intravenous ketamine was found to have relatively mild and short-lasting side effects in patients with treatment-resistant depression. The most common side effect was feeling strange or loopy, which peaked within an hour and resolved within two hours.
A study published in Thorax confirms that ICU patients experience delayed return-to-work and joblessness, with 20-27% requiring disability benefits at one year. Survivors incur substantial lost earnings, impacting quality of life.
New research presents alarming findings on ketamine infusion therapy for pain management, revealing that over a third of patients experience hallucinations, visual disturbances, and other adverse effects. The study emphasizes the importance of cautious approach to using ketamine as an opioid alternative.
The new AR head-mounted display delivers a realistic 3D viewing experience with an enlarged eye-box and increased field of view. It uses pixel beam scanning to keep images in focus regardless of distance, resulting in high-quality images without dispersion.
A new peanut allergy treatment, sublingual immunotherapy (SLIT), has shown effectiveness in protecting patients from severe allergic reactions. SLIT involves placing tiny amounts of peanut protein under the tongue, where it is absorbed immediately into the bloodstream, desensitizing the immune system to larger amounts of peanut protein.
Scientists identified a receptor, GPR139, in nematodes that decreases opioid sensitivity and withdrawal effects. The discovery could pave the way for developing new treatments with improved safety and efficacy.
Scientists at Oregon State University have discovered a protein modification that enables tumor cells to proliferate without harming healthy cells. This finding opens up new avenues for cancer therapies with minimal side effects.
Researchers found that a soybean antioxidant compound blocked damage to blood vessels in laboratory tests, potentially preventing cardiovascular side effects of recreational and medical marijuana use. The study suggests JW-1 could be a new way to protect blood vessels without psychiatric side effects.
A new class of drug lead derived from N-arylpyrrole exhibits potent anesthetic activity with minimal blood pressure suppression, suggesting a safer alternative to traditional anesthetics. The compound shows promise in tadpoles and rats, providing hope for improved patient safety.
Researchers found that every fourth osteoarthritis patient was prescribed opioids, with codeine and tramadol being the most commonly used. Despite not being recommended as a first-line treatment, opioids were still given to nearly a quarter of patients, highlighting a significant challenge in addressing osteoarthritis pain management.
Researchers have discovered a new treatment approach for T-cell acute lymphoblastic leukemia (T-ALL) that targets the Notch signaling pathway with greater safety and efficacy than previous treatments. The findings, published in Science Translational Medicine, show promise for translating this therapy to patients.
A study led by Washington University School of Medicine found that proton therapy results in fewer side effects than traditional X-ray radiation therapy for many cancer patients, with similar cure rates. Proton therapy reduced the risk of severe side effects by two-thirds within 90 days of treatment.
A recent study published in Journal of Thoracic Oncology found that about 3% of brigatinib patients experience shortness of breath within hours of starting the drug. However, with appropriate supportive care, most patients can rapidly build tolerance and continue on the drug without incident.
Anabolic steroids pose significant health risks, including damaged sperm and increased risk of heart disease and liver damage. Men are often aware of these risks but choose to continue using steroids to improve strength and physical performance.
A combination of biological markers and genetic changes can predict radiation sensitivity, helping doctors assess patients at risk of side effects. The study found that the time of day when radiotherapy is given can also affect side effects, particularly in breast cancer patients.
A new CAR molecule has been developed that kills cancer cells with less toxicity, allowing for remissions without serious side effects. Researchers have produced no severe side effects in patients with lymphoma, showing promise for a safer version of the therapy
A scientific breakthrough provides new hope for people with multiple sclerosis, as researchers have developed a compound that stimulates repair of the protective sheath that covers nerve cells in the brain and spinal cord. The study, published in JCI Insight, shows promising results in repairing damaged myelin without severe side effects.
Researchers have captured the full-length structure of PDE6, an enzyme linked to vision problems and potential side effects from erectile dysfunction medications like sildenafil. The study reveals fish-hook-like regions that could be targeted for new inhibitors.
A recent UBC study found that a 'reduced workload' program is the best option for men recovering from a radical prostatectomy, reducing the risk of burnout and promoting full recovery. The researchers recommend that patients have an open conversation with their employer before surgery to come up with a plan for a gradual return to work.